Kala Bio Enters Letter of Intent for U.S. Distribution Partnership with Virotek in Ophthalmology Genetic Testing
Kala Bio (NASDAQ: KALA) has signed a letter of intent to become the exclusive U.S. distributor and reseller of Virotek's ophthalmology genetic testing program, aiming to generate near-term revenue through its established commercial infrastructure. The partnership would allow Kala to leverage its prior experience in ophthalmology while limiting operational responsibilities by having Virotek manage laboratory operations, specimen processing, kit fulfillment, and clinical reporting. The companies are targeting definitive agreements within 30 days, though the deal remains subject to corporate, regulatory, and Nasdaq approvals. This move represents a strategic return for Kala into commercial activity in ophthalmology after selling its previous franchise to Alcon in 2022. While not guaranteeing revenue generation or transaction completion, this partnership could expand Kala's market presence and potentially open doors for future collaborations beyond genetic testing.
Topics: distribution partnership genetic testing ophthalmology